210 related articles for article (PubMed ID: 37444554)
1. Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation.
Willing EM; Vollbrecht C; Vössing C; Weist P; Schallenberg S; Herbst JM; Schatz S; Jóri B; Bataillon G; Harter P; Salutari V; Martin AG; Vergote I; Colombo N; Roeper J; Berg T; Berger R; Kah B; Noettrup TJ; Falk M; Arndt K; Polten A; Ray-Coquard I; Selzam F; Pirngruber J; Schmidt S; Hummel M; Tiemann M; Horst D; Sehouli J; Pujade-Lauraine E; Tiemann K; Braicu EI; Heukamp LC
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444554
[TBL] [Abstract][Full Text] [Related]
2. Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.
Pujade-Lauraine E; Brown J; Barnicle A; Wessen J; Lao-Sirieix P; Criscione SW; du Bois A; Lorusso D; Romero I; Petru E; Yoshida H; Vergote I; Colombo N; Hietanen S; Provansal M; Schmalfeldt B; Pignata S; Martín Lorente C; Berton D; Runnebaum IB; Ray-Coquard I
JCO Precis Oncol; 2023 Jan; 7():e2200258. PubMed ID: 36716415
[TBL] [Abstract][Full Text] [Related]
3. High Concordance of Different Assays in the Determination of Homologous Recombination Deficiency-Associated Genomic Instability in Ovarian Cancer.
Pfarr N; von Schwarzenberg K; Zocholl D; Merkelbach-Bruse S; Siemanowski J; Mayr EM; Herold S; Kleo K; Heukamp LC; Willing EM; Menzel M; Lehmann U; Bartels S; Chakraborty S; Baretton G; Demes MC; Döring C; Kazdal D; Budczies J; Rad R; Wild P; Christinat Y; McKee T; Schirmacher P; Horst D; Büttner R; Stenzinger A; Sehouli J; Vollbrecht C; Hummel M; Braicu EI; Weichert W;
JCO Precis Oncol; 2024 Mar; 8():e2300348. PubMed ID: 38513168
[TBL] [Abstract][Full Text] [Related]
4. In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay.
Fumagalli C; Betella I; Ranghiero A; Guerini-Rocco E; Bonaldo G; Rappa A; Vacirca D; Colombo N; Barberis M
Pathologica; 2022 Aug; 114(4):288-294. PubMed ID: 36136896
[TBL] [Abstract][Full Text] [Related]
5. RediScore: Prospective validation of a pipeline for homologous recombination deficiency analysis.
Tsantikidi A; Papazisis K; Floros T; Gazouli M; Papadopoulou E; Tsaousis G; Nasioulas G; Mester A; Milan KP; Gozman B; Afrasanie V; Stanculeanu DL; Trifanescu O; Pescaru F; Militaru C; Papadimitriou C
Oncol Lett; 2023 Nov; 26(5):480. PubMed ID: 37809048
[TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer.
Boidot R; Blum MGB; Wissler MP; Gottin C; Ruzicka J; Chevrier S; Delhomme TM; Audoux J; Jeanniard A; Just PA; Harter P; Pignata S; González-Martin A; Marth C; Mäenpää J; Colombo N; Vergote I; Fujiwara K; Duforet-Frebourg N; Bertrand D; Philippe N; Ray-Coquard I; Pujade-Lauraine E;
Eur J Cancer; 2024 May; 202():113978. PubMed ID: 38471290
[TBL] [Abstract][Full Text] [Related]
7. Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma.
Christinat Y; Ho L; Clément S; Genestie C; Sehouli J; Cinieri S; Gonzalez Martin A; Denison U; Fujiwara K; Vergote I; Tognon G; Hietanen S; Ray-Coquard I; Pujade-Lauraine E; McKee TA
JCO Precis Oncol; 2023 Jun; 7():e2200555. PubMed ID: 37364234
[TBL] [Abstract][Full Text] [Related]
8. Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study.
Morgan RD; Clamp AR; Barnes BM; Timms K; Schlecht H; Yarram-Smith L; Wallis Y; Valganon-Petrizan M; MacMahon S; White R; Morgan S; McKenna S; Hudson E; Tookman L; George A; Manchanda R; Sundar SS; Nicum S; Brenton JD; Kristeleit RS; Banerjee S; McNeish IA; Ledermann JA; Taylor SS; Evans DGR; Jayson GC
Int J Gynecol Cancer; 2023 Aug; 33(8):1253-1259. PubMed ID: 37072323
[TBL] [Abstract][Full Text] [Related]
9. PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial.
Loverix L; Vergote I; Busschaert P; Vanderstichele A; Venken T; Boeckx B; Harter P; Brems H; Van Nieuwenhuysen E; Pignata S; Baert T; Gonzalez-Martin A; Han S; Marth C; Neven P; Colombo N; Berteloot P; Mäenpää J; Olbrecht S; Laga T; Sablon E; Ray-Coquard I; Pujade-Lauraine E; Lambrechts D; Van Gorp T
Eur J Cancer; 2023 Jul; 188():131-139. PubMed ID: 37245441
[TBL] [Abstract][Full Text] [Related]
10. Systematic Analysis of Homologous Recombination Deficiency Testing in Ovarian Cancer-Development of Recommendations for Optimal Assay Performance.
Romey M; Rodepeter F; Hattesohl A; Kaiser K; Teply-Szymanski J; Heitz F; Staebler A; Serra V; Grass A; Marmé F; Timms KM; Harter P; Llop-Guevara A; Kommoss S; Boekhoff J; Denkert C
Mod Pathol; 2024 Apr; 37(4):100445. PubMed ID: 38341130
[TBL] [Abstract][Full Text] [Related]
11. Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis.
Batalini F; DaSilva LL; Campoverde L; Comini ACM; Carvalho BM; Nogueira W; Silveira H; Ernst BJ; Mina LA
Chin Clin Oncol; 2023 Jun; 12(3):21. PubMed ID: 37211773
[TBL] [Abstract][Full Text] [Related]
12. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
[TBL] [Abstract][Full Text] [Related]
13. Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial.
Callens C; Rodrigues M; Briaux A; Frouin E; Eeckhoutte A; Pujade-Lauraine E; Renault V; Stoppa-Lyonnet D; Bieche I; Bataillon G; Karayan-Tapon L; Rochelle T; Heitz F; Cecere SC; Pérez MJR; Grimm C; Nøttrup TJ; Colombo N; Vergote I; Yonemori K; Ray-Coquard I; Stern MH; Popova T
Oncogene; 2023 Nov; 42(48):3556-3563. PubMed ID: 37945748
[TBL] [Abstract][Full Text] [Related]
14. Homologous Recombination Deficiency as an Ovarian Cancer Biomarker in a Real-World Cohort: Validation of Decentralized Genomic Profiling.
Denkert C; Romey M; Swedlund B; Hattesohl A; Teply-Szymanski J; Kommoss S; Kaiser K; Staebler A; du Bois A; Grass A; Knappmeyer C; Heitz F; Solimeno C; Ebel T; Harter P; Marmé F; Jank P; Gaiser T; Neff C; Wagner U; Timms KM; Rodepeter F
J Mol Diagn; 2022 Dec; 24(12):1254-1263. PubMed ID: 36191839
[TBL] [Abstract][Full Text] [Related]
15. Concordance between Three Homologous Recombination Deficiency (HRD) Assays in Patients with High-Grade Epithelial Ovarian Cancer.
Fountzilas E; Papadopoulou K; Chatzikonstantinou T; Karakatsoulis G; Constantoulakis P; Tsantikidi A; Tsaousis G; Karageorgopoulou S; Koumarianou A; Mauri D; Ntavatzikos A; Saridaki Z; Petrakis G; Fostira F; Fountzilas G; Liontos M
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067228
[TBL] [Abstract][Full Text] [Related]
16. NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial.
Endris V; Stenzinger A; Pfarr N; Penzel R; Möbs M; Lenze D; Darb-Esfahani S; Hummel M; Sabine-Merkelbach-Bruse ; Jung A; Lehmann U; Kreipe H; Kirchner T; Büttner R; Jochum W; Höfler G; Dietel M; Weichert W; Schirmacher P
Virchows Arch; 2016 Jun; 468(6):697-705. PubMed ID: 27003155
[TBL] [Abstract][Full Text] [Related]
17. Homologous recombination deficiency real-time clinical assays, ready or not?
Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
[TBL] [Abstract][Full Text] [Related]
18. Concordance between an FDA-approved companion diagnostic and an alternative assay kit for assessing homologous recombination deficiency in ovarian cancer.
Wehn AK; Qiu P; Lunceford J; Yarunin A; Cristescu R; Liu L; Roessler K; Bilke S; Day JR; Timms KM; Weichert W; Marton MJ
Gynecol Oncol; 2024 Jan; 184():67-73. PubMed ID: 38290412
[TBL] [Abstract][Full Text] [Related]
19. Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes.
Pikkusaari S; Tumiati M; Virtanen A; Oikkonen J; Li Y; Perez-Villatoro F; Muranen T; Salko M; Huhtinen K; Kanerva A; Koskela H; Tapper J; Koivisto-Korander R; Joutsiniemi T; Haltia UM; Lassus H; Hautaniemi S; Färkkilä A; Hynninen J; Hietanen S; Carpén O; Kauppi L
Clin Cancer Res; 2023 Aug; 29(16):3110-3123. PubMed ID: 36805632
[TBL] [Abstract][Full Text] [Related]
20. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.
Ray-Coquard I; Leary A; Pignata S; Cropet C; González-Martín A; Marth C; Nagao S; Vergote I; Colombo N; Mäenpää J; Selle F; Sehouli J; Lorusso D; Guerra Alia EM; Bogner G; Yoshida H; Lefeuvre-Plesse C; Buderath P; Mosconi AM; Lortholary A; Burges A; Medioni J; El-Balat A; Rodrigues M; Park-Simon TW; Dubot C; Denschlag D; You B; Pujade-Lauraine E; Harter P;
Ann Oncol; 2023 Aug; 34(8):681-692. PubMed ID: 37211045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
